News
AstraZeneca (LSE:AZN) Launches FluMist Home For At-Home Influenza Vaccination
AstraZeneca (LSE:AZN) recently launched "FluMist Home," an at-home flu vaccine delivery service, marking an important milestone for easier access to vaccinations in 34 U.S. states. This initiative likely contributed to its stock price increase of 12% last quarter,
AstraZeneca PLC closed 12.32% short of its 52-week high of £133.88, which the company achieved on September 3rd.
The treatment is one for those suffering with lung cancer who never smoked, a group of patients who account for up to 25% of those who develop the disease due to an oncogenic driver mutation. Tagrisso ...
AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...
Stocktwits on MSN10h
Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca
FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong ...
Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...
He said about Britain that the firm needed “to see that there is access and a reason to invest.” This is partly a negotiating tactic to get a better deal from the British government, including on what ...
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for AstraZeneca’s ...
While the numbers may seem high, they are still far below the pay of top executives in the United States, the study has found ...
AstraZeneca has launched FluMist Home, a nasal spray flu vaccine with at-home delivery service. For those who have a needle ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback